Other Events ·
GoodRx restates Q1 and Q2 2026 results after understating Pharma Direct revenue by up to $29.8M
GDRXGoodRx Holdings, Inc.
GoodRx Holdings announced that its Audit and Risk Committee concluded the company's condensed consolidated financial statements for the fiscal quarters ended March 31, 2026, and June 30, 2026, should no longer be relied upon due to an understatement of Pharma Direct revenue. The error resulted from revenue recognition issues under ASC 606, requiring restatements that increase total revenue by $7.5 million for Q1 and $22.3 million for Q2. Consequently, net income is adjusted upward by $3.8 million in the first quarter and $11.1 million in the second. The company expects to report material weaknesses in internal control over financial reporting for these periods and plans to file amended 10-Q forms as soon as practicable. GoodRx operates a digital health platform that provides prescription drug discount coupons and pricing information.